RHB-204, Oral Treatment for MAC Lung Infections, Put on FDA Fast Track
Jan 08, 2021 09:30 am | Marta Figueiredo
The U.S. Food and Drug Administration (FDA) has given fast track designation to RedHill Biopharma’s RHB-204 as a potential first-line and stand-alone, oral treatment for lung infections caused by Mycobacterium avium complex (MAC), a type of non-tuberculous mycobacteria (NTM). This designation is given to therapies that show considerable potential in addressing serious conditions for which […]
The post RHB-204, Oral Treatment for MAC Lung Infections, Put on FDA Fast Track appeared first on Bronchiectasis News Today.